secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
CIK:        0001100682
Form:       8-K
Filed at:   2024-02-14T23:59:59+00:00
Accession:  0001157523-24-000238
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Charles River Q4 2023 revenue down 7.9% to $1.01B; non-GAAP EPS $2.46; 2024 guidance organic growth 0-3%
--------------------------------------------------------------------------------

- Q4 GAAP EPS $3.62 vs $3.65 YoY; non-GAAP EPS $2.46 vs $2.98, down 17.4%.
- Full-year 2023 revenue $4.13B (+3.9%); GAAP EPS $9.22; non-GAAP EPS $10.67.
- 2024 guidance: organic revenue growth 0%-3%; GAAP EPS $7.90-$8.40; non-GAAP EPS $10.90-$11.40.
- Noveprim acquisition completed Nov 2023 (additional 41% stake for $144.6M, now 90% controlling interest).
- DSA segment revenue fell 9.5% in Q4; Manufacturing organic growth +2.3% but revenue down 9.5%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1100682/000115752324000238/0001157523-24-000238-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1100682/000115752324000238/a53896037.htm
  HTML page:      https://secwatch.observer/filing/0001157523-24-000238

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer